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PD-L1 expressed in the tumor microenvironment regu-
lates Th1 immune responses and mediates cancer
immune evasion through interactions with PD-1 or B7.1
receptors on activated T cells. MPDL3280A, an engi-
neered human monoclonal antibody, targets PD-L1 and
inhibits its function. To identify immunologic predictive
and pharmacodynamic biomarkers of MPDL3280A treat-
ment, we performed a comprehensive analysis of tumors
and blood samples collected at baseline and/or on treat-
ment from ≈280 patients with locally advanced or meta-
static solid tumors, including NSCLC, RCC, melanoma
and bladder cancer. Regardless of tumor type, clinical
responses were characterized by PD-L1 expression, the
presence of markers of T cell activation (Th1 gene signa-
ture and CTLA4), and the absence of fractalkine at base-
line in the tumor microenvironment. Elevated baseline
expression of IFN-g and IFN-g-inducible genes (e.g.,
IDO1 and CXCL9) was associated with MPDL3280A
response in melanoma but not NSCLC or RCC. On treat-
ment, responding tumors showed increased infiltration of
Th1-dominant immune infiltrate and evidence of adap-
tive PD-L1 up-regulation. In contrast, progressing tumors
displayed the following patterns of tumor-infiltrating
lymphocytes (TILs) and PD-L1 expression: (1) few/no
TILs and absent PD-L1 expression (immunologic ignor-
ance), (2) TILs present with minimal/no PD-L1 expres-
sion (non-functional immune responses), or (3) TILs
residing solely around the tumor cell mass outer edge
(excluded infiltrate), suggesting that resistance to
MPDL3280A may be associated with impaired T cell traf-
ficking and/or function.
Profiling of ≈180 circulating biomarkers revealed that
plasma concentrations of IL-18 and interferon-inducible T
cell alpha chemoattractant (ITAC) increased in all patients
following MPDL3280A treatment, representing a pharma-
codynamic measurement of PD-L1 inhibition. In addition,
analysis of PBMC showed an increase in T cell activation,
as measured by IFN-g and granzymes A and B gene expres-
sion in responders following MPDL3280A treatment, con-
sistent with the observations in responding tumors.
Baseline soluble PD-L1 was not associated with response.
Some indication-specific biomarkers, such as plasma
VEGF, decreased in responders with RCC but not with
other indications. In NSCLC, a decrease in tumor burden
markers, CA-125 and CEA, was associated with response.
Similarly, IL-6 and IL-8 were differentially expressed on
treatment in responders vs non-responders. Additionally,
responders exhibited a decrease in circulating tumor DNA
(ctDNA) in plasma, suggesting that ctDNA may be used to
monitor MPDL3280A clinical activity in NSCLC.
In conclusion, these data provide general and indication-
specific mechanistic insights into immune checkpoint
inhibition, potential mechanisms of response and resis-
tance, as well as identification of potential predictive and
pharmacodynamic biomarkers of anti-PD-L1/PD-1 clinical
activity across multiple tumor types.
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